| Literature DB >> 32204502 |
Mateusz Maciejczyk1, Katarzyna Taranta-Janusz2, Anna Wasilewska2, Agnieszka Kossakowska3, Anna Zalewska3.
Abstract
Oxidative stress plays a critical role in the pathogenesis of hypertension; however, there are no data on salivary redox homeostasis and salivary gland function in children with hypertension. A total of 53 children with hypertension and age- and sex-matched controls were classified for the study. The antioxidant barrier and oxidative/nitrosative stress were evaluated in non-stimulated (NWS) and stimulated (SWS) whole saliva, plasma, and erythrocytes, with Student's t-test and Mann-Whitney U-test used for statistical analysis. We demonstrated that the activities of superoxide dismutase, catalase, and peroxidase were significantly higher in NWS, SWS, and erythrocytes of children with hypertension, similar to oxidative damage in proteins (advanced glycation end products) and lipids (malondialdehyde) as well as nitrosative stress markers (peroxynitrite and nitrotyrosine). The level of uric acid (UA) was significantly higher in NWS, SWS, and plasma of children with hypertension. UA concentration in SWS correlated positively with systolic and diastolic blood pressure and UA content in plasma. This parameter differentiates children with hypertension from healthy controls (AUC = 0.98) with a high degree of sensitivity (94%) and specificity (94%). Stimulated salivary flow was significantly lower in the hypertension group, similar to total protein content and salivary amylase activity. In summary, childhood hypertension is associated with hyposalivation as well as disturbances in antioxidant defense and enhanced oxidative/nitrosative damage both in the plasma/erythrocytes as well as saliva. Salivary UA may be a potential biomarker of hypertension in children.Entities:
Keywords: hypertension; oxidative stress; redox homeostasis; salivary antioxidants; salivary biomarkers
Year: 2020 PMID: 32204502 PMCID: PMC7141280 DOI: 10.3390/jcm9030837
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Clinical characteristics of children with hypertension and healthy controls.
| Control | Hypertension | ||
|---|---|---|---|
| General Data | |||
| Age (years) | 13 ± 3.1 | 13 ± 3.5 | |
| Male | 28 (53%) | 28 (53%) | |
| BMI (kg/m2) | 22 ± 2.6 | 26 ± 5.9 * | |
| SDS BMI | 0.8 ± 0.2 | 2.4 ± 0.5 | |
| Obesity | 0 (0) | 20 (38%) | |
| Blood Pressure | |||
| SBP (mmHg) | 106 ± 10.5 | 124 ± 12 * | |
| DBP (mmHg) | 65 ± 8 | 76 ± 9.5 * | |
| Blood Tests | |||
| WBC (tys./μL) | 7.5 ± 0.9 | 6.8 ± 1.7 | |
| RBC (tys./μL) | 4.3 ± 0.5 | 4.3 ± 0.2 | |
| Hgb (g/dL) | 14 ± 0.9 | 14 ± 1.3 | |
| Hct (%) | 43 ± 2.6 | 42 ± 3.7 | |
| PLT (tys./μL) | 250 ± 65 | 274 ± 60 | |
| sCre (mg/dL) | 0.73 ± 0.5 | 0.73 ± 0.4 | |
| sUrea (mg/dL) | 15 ± 10 | 25 ± 11 | |
| HDL (mg/dL) | 52 ± 10 | 48 ± 12 | |
| LDL (mg/dL) | 70 ± 25 | 97 ± 24 * | |
| TC (mg/dL) | 167 ± 45 | 177 ± 74 | |
| TG (mg/dL) | 70 ± 38 | 122 ± 72 * | |
| Glucose (mg/dL) | 82 ± 5.5 | 89 ± 7.9 | |
| IL-6 (pg/mL) | 1.44 ± 0.57 | 2.49 ± 0.58 * | |
| eGFR (mL/min/1.73m2) | 140 ± 29 | 118 ± 38 | |
| Pharmacotherapy | |||
| Hypotensive drugs | 0 per day | 0 (0) | 22 (39) |
| 1 per day | 0 (0) | 24 (45) | |
| 2 per day | 0 (0) | 7 (13) | |
| Angiotensin-converting enzyme inhibitors | 0 (0) | 21 (40) | |
| Angiotensin receptor blockers | 0 (0) | 5 (9) | |
| Calcium channel blockers | 0 (0) | 4 (7) | |
BMI—Body Mass Index; DBP—diastolic blood pressure; eGFR—estimated glomerular filtration rate; Hct—hematocrit; HDL—high-density lipoprotein; Hgb—hemoglobin; LDL—low-density lipoprotein; PLT—platelet; SBP—systolic blood pressure; sCre—serum creatinine; sUrea—serum Urea; TC—total cholesterol; TG—triglycerides; WBC—white blood cells. * p < 0.05 vs. the control group.
Summary of ABPM profiles in hypertensive children.
| 24 h SBP (mmHg) | 127 ± 11 |
| 24 h DBP (mmHg) | 69 ± 7.5 |
| SBP daytime (mmHg) | 130 ± 11 |
| DBP daytime (mmHg) | 72 ± 7.6 |
| SBP nighttime (mmHg) | 117 ± 11 |
| DBP nighttime (mmHg) | 72 ± 16 |
| SBPL daytime (%) | 51 ± 3.7 |
| DBPL daytime (%) | 19 ± 3.0 |
| SBPL nighttime (%) | 47 ± 4.6 |
| DBPL nighttime (%) | 20 ± 2.8 |
| SBP 24 h Z-score | 0.21 ± 5.9 |
| DBP 24 h Z-score | 0.25 ± 2.2 |
| SBP day Z-score | 0.91 ± 2.5 |
| DBP day Z-score | 136 ± 675 |
| SBP night Z-score | -7 ± 20 |
| DBP night Z-score | -7.9 ± 29 |
ABPM—ambulatory blood pressure monitoring; DBP—diastolic blood pressure; SBP—systolic blood pressure; DBPL—diastolic blood pressure load; SBPL—systolic blood pressure load.
Salivary gland function and dental examination of children with hypertension and healthy controls.
| Control | Hypertension | |
|---|---|---|
| NWS flow (mL/min) | 0.47 ± 0.05 | 0.43 ± 0.05 |
| SWS flow (mL/min) | 1.8 ± 0.09 | 0.89 ± 0.09 * |
| TP NWS (μg/mL) | 1350 ± 185 | 1330 ± 264 |
| TP SWS (μg/mL) | 1019 ± 217 | 772 ± 228 * |
| α-amylase NWS (μmol/mg protein) | 0.2 ± 0.08 | 0.19 ± 0.08 |
| α-amylase SWS (μmol/mg protein) | 0.28 ± 0.05 | 0.21 ± 0.08 * |
| DMFT | 3.1 ± 0.1 | 3.1 ± 0.2 |
| dmft | 11 ± 0.1 | 11.1 ± 0.1 |
| PBI | 0 ± 0.1 | 0 ± 0.1 |
| GI | 0 ± 0.1 | 0 ± 0.1 |
DMFT—decay, missing, filled of permanent teeth; dmft—decay, missing, filled of milk teeth; PBI—Papilla Bleeding Index; GI—Gingival Index; NWS—non-stimulated whole saliva; SWS—stimulated whole saliva; TP—total protein content. * p < 0.05 vs. the control group.
Figure 1Antioxidant enzymes in children with hypertension and healthy controls. CAT—catalase; GPx—glutathione peroxidase; NWS—non-stimulated whole saliva; Px—salivary peroxidase; SOD—superoxide dismutase; SWS—stimulated whole saliva. Differences statistically significant at: *** p < 0.001 (Student’s t-test); ^^^ p < 0.001 (Mann–Whitney U-test).
Figure 2Non-enzymatic antioxidants in children with hypertension and healthy controls. GSH—reduced glutathione; NWS—non-stimulated whole saliva; SWS—stimulated whole saliva; UA—uric acid. Differences statistically significant at: ** p < 0.01, *** p < 0.001 (Student’s t-test); ^^^ p < 0.001 (Mann–Whitney U-test).
Figure 3Redox status in children with hypertension and healthy controls. NWS —non-stimulated whole saliva; OSI—oxidative stress index; SWS—stimulated whole saliva; TAC—total antioxidant capacity; TOS—total oxidant status. Differences statistically significant at: * p < 0.05, *** p < 0.001 (Student’s t-test); ^^^ p < 0.001 (Mann–Whitney U-test).
Figure 4Oxidative stress products in children with hypertension and healthy controls. AGE—advanced glycation end products; MDA—malondialdehyde; NWS—non-stimulated whole saliva; SWS—stimulated whole saliva. Differences statistically significant at: *** p < 0.001 (Student’s t-test).
Figure 5Nitrosative stress in children with hypertension and healthy controls. NO—nitric oxide; NWS—non-stimulated whole saliva; SWS—stimulated whole saliva. Differences statistically significant at: ** p < 0.01, *** p < 0.001 (Student’s t-test).
Correlations between salivary redox biomarkers and clinical characteristics in the control group.
| Pair of Variables | r |
|
|---|---|---|
| SWS | ||
| CAT and SOD | 0.32 | 0.028 |
| Saliva and blood | ||
| AGE NWS and AGE plasma | 0.83 | <0.001 |
| MDA NWS and MDA plasma | 0.83 | <0.001 |
CAT—catalase; SOD—superoxide dismutase; NWS—non-stimulated whole saliva; SWS—stimulated whole saliva.
Correlations between salivary redox biomarkers and clinical characteristics in children with hypertension.
| Pair of Variables | r |
|
|---|---|---|
| NWS | ||
| SOD and TOS | 0.83 | <0.001 |
| MDA and SBP | 0.64 | <0.001 |
| MDA and SBP | 0.49 | 0.001 |
| SWS | ||
| CAT and TOS | 0.75 | <0.001 |
| UA and TOS | 0.62 | <0.001 |
| UA and DBP | 0.8 | <0.001 |
| AGE and SBP | 0.64 | <0.001 |
| AGE and DBP | 0.5 | 0.001 |
| MDA and SBP | 0.6 | <0.001 |
| MDA and DBP | 0.31 | 0.025 |
| UA and DBP | 0.8 | <0.001 |
| UA and DBP 24 h Z-score | 0.35 | 0.016 |
| UA and SBP 24 h Z-score | 0.41 | 0.004 |
| GSH and Peroxynitrite | -0.61 | <0.001 |
| Peroxynitrite and MDA | 0.61 | <0.001 |
| Peroxynitrite and nitrotyrosine | 0.68 | <0.001 |
| SWS flow and MDA | −0.77 | <0.001 |
| SWS flow and NO | 0.56 | <0.001 |
| SWS flow and peroxynitrite | −0.42 | 0.002 |
| SWS flow and nitrotyrosine | −0.41 | 0.002 |
| Saliva and blood | ||
| AGE NWS and AGE plasma | 0.8 | <0.001 |
| MDA NWS and MDA plasma | 0.89 | <0.001 |
| UA SWS and IL-6 | 0.72 | <0.001 |
AGE—advanced glycation end products; CAT—catalase; DBP—diastolic blood pressure; GSH—reduced glutathione; MDA—malondialdehyde; NO—nitric oxide; NWS—non-stimulated whole saliva; SBP—systolic blood pressure; SOD—superoxide dismutase; SWS—stimulated whole saliva; TOS—total oxidant status; UA—uric acid.
Receiver operating characteristic (ROC) analysis of redox biomarkers in non-stimulated and stimulated saliva of children with hypertension and the control subjects.
| AUC | Confidence Intervals | Cut-off | Sensitivity (%) | Specificity (%) | ||
|---|---|---|---|---|---|---|
| NWS | ||||||
| SOD (mU/mg protein) | 0.91 | 0.86–0.96 | <0.001 | >1.65 | 77 | 83 |
| CAT (nmol H2O2/min/mg protein) | 0.68 | 0.58–0.78 | 0.002 | >0.52 | 64 | 66 |
| Px (mU/mg protein) | 0.55 | 0.43–0.67 | 0.406 | >0.49 | 55 | 64 |
| GSH (µg/mg protein) | 0.87 | 0.80–0.94 | <0.001 | <0.43 | 79 | 79 |
| UA (µg/mg protein) | 0.85 | 0.77–0.92 | <0.001 | >3.35 | 72 | 79 |
| TAC (µmol/mg protein) | 0.83 | 0.74–0.92 | <0.001 | >0.59 | 77 | 82 |
| TOS (nmol H2O2 equiv/mg protein) | 0.87 | 0.79–0.95 | <0.001 | >10.30 | 81 | 87 |
| OSI (TOS/TAC ratio) | 0.58 | 0.47–0.68 | 0.186 | >13.45 | 57 | 55 |
| AGE (AFU/mg protein) | 0.96 | 0.92–1.00 | <0.001 | >2.08 | 92 | 92 |
| MDA (µmol/mg protein) | 0.79 | 0.70–0.87 | <0.001 | >101.3 | 75 | 74 |
| NO (nmol/mg protein) | 0.63 | 0.52–0.73 | 0.026 | <180.6 | 62 | 58 |
| Peroxynitrite (pmol/mg protein) | 0.79 | 0.69–0.89 | <0.001 | >63.47 | 75 | 77 |
| Nitrotyrosine (pmol/mg protein) | 0.63 | 0.53–0.74 | 0.018 | >221.3 | 64 | 60 |
| SWS | ||||||
| SOD (mU/mg protein) | 0.74 | 0.65–0.84 | <0.001 | >3.72 | 74 | 70 |
| CAT (nmol H2O2/min/mg protein) | 0.93 | 0.87–0.98 | <0.001 | >5.11 | 91 | 91 |
| Px (mU/mg protein) | 0.79 | 0.70–0.88 | <0.001 | >0.47 | 77 | 72 |
| GSH (µg/mg protein) | 0.79 | 0.70–0.88 | <0.001 | <0.70 | 70 | 70 |
| UA (µg/mg protein) | 0.98 | 0.96–1.00 | <0.001 | >5.50 | 94 | 96 |
| TAC (µmol/mg protein) | 0.80 | 0.71–0.88 | <0.001 | >0.82 | 74 | 75 |
| TOS (nmol H2O2 equiv/mg protein) | 0.61 | 0.50–0.72 | 0.055 | >19.37 | 55 | 58 |
| OSI (TOS/TAC ratio) | 0.64 | 0.53–0.74 | 0.015 | <22.30 | 58 | 55 |
| AGE (AFU/mg protein) | 0.99 | 0.97–1.00 | <0.001 | >4.64 | 92 | 92 |
| MDA (µmol/mg protein) | 0.80 | 0.72–0.89 | <0.001 | >68.72 | 77 | 74 |
| NO (nmol/mg protein) | 0.83 | 0.75–0.91 | <0.001 | <197.7 | 74 | 77 |
| Peroxynitrite (pmol/mg protein) | 0.84 | 0.76–0.92 | <0.001 | >72.86 | 83 | 79 |
| Nitrotyrosine (pmol/mg protein) | 0.72 | 0.62–0.82 | 0.001 | >204.5 | 66 | 66 |
AGE—advanced glycation end products; AUC—area under the curve; CAT—catalase; GPx—glutathione peroxidase; GSH—reduced glutathione; MDA—malondialdehyde; NWS—non-stimulated whole saliva; Px—salivary peroxidase; SOD—superoxide dismutase; SWS—stimulated whole saliva; TAC—total antioxidant capacity; TOS—total oxidant status; UA—uric acid.
Receiver operating characteristic (ROC) analysis of redox biomarkers in erythrocytes/plasma of children with hypertension and the control subjects.
| AUC | Confidence Intervals | Cut-off | Sensitivity (%) | Specificity (%) | ||
|---|---|---|---|---|---|---|
| Erythrocytes | ||||||
| SOD (mU/mg protein) | 0.89 | 0.83–0.96 | <0.001 | >0.37 | 83 | 83 |
| CAT (nmol H2O2/min/mg protein) | 0.85 | 0.77–0.92 | <0.001 | >0.43 | 79 | 79 |
| GPx (mU/mg protein) | 1.00 | 1.00–1.00 | <0.001 | >0.23 | 100 | 98 |
| Plasma | ||||||
| GSH (µg/mg protein) | 0.70 | 0.59–0.80 | 0.001 | <3.19 | 64 | 68 |
| UA (µg/mg protein) | 0.68 | 0.58–0.78 | 0.002 | >0.81 | 64 | 66 |
| TAC (µmol/mg protein) | 0.85 | 0.77–0.94 | <0.001 | >0.62 | 81 | 85 |
| TOS (nmol H2O2 equiv/mg protein) | 0.76 | 0.67–0.86 | <0.001 | >7.95 | 77 | 74 |
| OSI (TOS/TAS ratio) | 0.57 | 0.46–0.68 | 0.226 | >13.45 | 57 | 55 |
| AGE (AFU/mg protein) | 1.00 | 1.00–1.00 | <0.001 | >3.96 | 98 | 100 |
| MDA (µmol/mg protein) | 0.90 | 0.84–0.97 | <0.001 | >103.7 | 85 | 92 |
| NO (nmol/mg protein) | 0.82 | 0.73–0.91 | <0.001 | <16.66 | 77 | 79 |
| Peroxynitrite (pmol/mg protein) | 0.78 | 0.68–0.87 | <0.001 | >86.27 | 72 | 74 |
| Nitrotyrosine (pmol/mg protein) | 0.67 | 0.57–0.77 | 0.003 | >166.2 | 68 | 64 |
AGE—advanced glycation end products; AUC—area under the curve; CAT—catalase; GPx—glutathione peroxidase; GSH—reduced glutathione; MDA—malondialdehyde; NWS—non-stimulated whole saliva; Px—salivary peroxidase; SOD—superoxide dismutase; SWS—stimulated whole saliva; TAC—total antioxidant capacity; TOS—total oxidant status; UA—uric acid.